Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
CRMD

CRMD - CorMedix Inc Stock Price, Fair Value and News

4.89USD-0.10 (-2.00%)Market Closed

Market Summary

CRMD
USD4.89-0.10
Market Closed
-2.00%

CRMD Stock Price

View Fullscreen

CRMD RSI Chart

CRMD Valuation

Market Cap

268.8M

Price/Earnings (Trailing)

-5.35

Price/Sales (Trailing)

4.5K

EV/EBITDA

-5.64

Price/Free Cashflow

-5.88

CRMD Price/Sales (Trailing)

CRMD Profitability

Operating Margin

100.00%

EBT Margin

-63433.82%

Return on Equity

-86.6%

Return on Assets

-73.85%

Free Cashflow Yield

-17%

CRMD Fundamentals

CRMD Revenue

CRMD Earnings

Earnings (TTM)

-50.2M

Earnings Growth (Yr)

-36.9%

Earnings Growth (Qtr)

1.95%

Breaking Down CRMD Revenue

Last 7 days

-5.9%

Last 30 days

-5.9%

Last 90 days

19.4%

Trailing 12 Months

-12.9%

How does CRMD drawdown profile look like?

CRMD Financial Health

Current Ratio

6.65

CRMD Investor Care

Shares Dilution (1Y)

24.65%

Diluted EPS (TTM)

-0.93

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
20230000
202227.2K39.9K52.7K65.4K
2021253.4K245.2K190.3K14.4K
2020193.6K174.8K208.3K239.2K
2019570.3K598.0K285.0K283.3K
2018313.0K184.4K495.8K429.8K
2017222.2K341.9K358.5K329.3K
2016220.3K116.8K125.3K224.1K
2015208.3K288.6K272.1K210.1K
2014000189.3K
20130000

Tracking the Latest Insider Buys and Sells of CorMedix Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 10, 2024
todisco joseph
sold (taxes)
-278,994
5.17
-53,964
chief executive officer
Mar 13, 2024
todisco joseph
bought
50,718
3.74
13,561
chief executive officer
Jan 12, 2024
todisco joseph
sold (taxes)
-47,820
3.47
-13,781
chief executive officer
Jan 12, 2024
masson-hurlburt elizabeth
sold (taxes)
-15,972
3.47
-4,603
evp, head of clinical ops.
Jan 12, 2024
masson-hurlburt elizabeth
acquired
-
-
50,000
evp, head of clinical ops.
Jan 12, 2024
todisco joseph
acquired
-
-
133,333
chief executive officer
Jan 12, 2024
david matthew t
sold (taxes)
-18,099
3.47
-5,216
chief financial officer
Jan 12, 2024
david matthew t
acquired
-
-
50,000
chief financial officer
Jan 12, 2024
mistry erin
sold (taxes)
-15,229
3.47
-4,389
chief commercial officer

1–10 of 50

Which funds bought or sold CRMD recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 24, 2024
Cetera Investment Advisers
new
-
51,524
51,524
-%
May 22, 2024
BURNEY CO/
unchanged
-
4,800
42,400
-%
May 20, 2024
Virtu Financial LLC
reduced
-60.56
-57,000
46,000
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-38.92
-10,587
23,430
-%
May 16, 2024
Tidal Investments LLC
new
-
59,805
59,805
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-68.47
-154,141
85,033
-%
May 15, 2024
Cubist Systematic Strategies, LLC
sold off
-100
-64,894
-
-%
May 15, 2024
DEUTSCHE BANK AG\
unchanged
-
13,742
121,379
-%
May 15, 2024
STATE STREET CORP
added
3.42
670,814
4,705,800
-%
May 15, 2024
WOLVERINE TRADING, LLC
reduced
-18.45
-4,869
55,671
-%

1–10 of 47

Are Funds Buying or Selling CRMD?

Are funds buying CRMD calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CRMD
No. of Funds

Unveiling CorMedix Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
nomura holdings inc
5.4%
2,946,531
SC 13G/A
Feb 13, 2024
vanguard group inc
5.15%
2,825,335
SC 13G
Jan 29, 2024
blackrock inc.
6.4%
3,507,695
SC 13G
Feb 14, 2023
nomura holdings inc
7.2%
2,952,334
SC 13G/A
Jul 08, 2022
blackrock inc.
1.6%
637,778
SC 13G
Feb 14, 2022
nomura holdings inc
5.3%
2,003,612
SC 13G
Feb 03, 2022
blackrock inc.
6.6%
2,500,721
SC 13G/A
Feb 11, 2021
elliott investment management l.p.
4.99%
7,136,979
SC 13D/A
Jan 29, 2021
blackrock inc.
6.2%
1,995,193
SC 13G/A
Aug 10, 2020
elliott investment management l.p.
5.8%
1,758,374
SC 13D

Recent SEC filings of CorMedix Inc

View All Filings
Date Filed Form Type Document
May 22, 2024
EFFECT
EFFECT
May 13, 2024
4
Insider Trading
May 09, 2024
S-3
S-3
May 09, 2024
8-K
Current Report
May 09, 2024
10-Q
Quarterly Report
Mar 20, 2024
4
Insider Trading
Mar 20, 2024
4
Insider Trading
Mar 20, 2024
4
Insider Trading
Mar 20, 2024
4
Insider Trading
Mar 20, 2024
4
Insider Trading

Peers (Alternatives to CorMedix Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
55.6B
6.8B
17.55% 15.42%
-9.32
8.12
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.2B
2.0B
6.10% -19.49%
-60.95
10.1
75.20% 68.82%
16.0B
2.5B
5.03% -10.77%
77.84
6.47
13.74% 186.89%
14.1B
3.8B
4.06% -3.24%
18.89
3.74
8.58% 129.81%
MID-CAP
5.4B
107.9M
0.63% 71.22%
-9.93
48.09
54.84% -28.31%
5.2B
524.1M
-1.19% -54.45%
-12.38
9.85
394.93% 39.61%
3.4B
251.0M
-5.41% -4.45%
-11.62
13.72
73.58% -86.73%
3.3B
240.7M
16.82% -26.89%
-6.96
12.77
-1.03% -213.92%
2.5B
813.8M
1.25% -38.59%
-1.5K
3.07
56.43% 98.83%
2.1B
996.6M
20.98% 97.26%
-5.3
2.12
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-4.75% 32.39%
27.77
4.4
60.38% -34.49%
564.4M
881.7K
19.55% 492.49%
-16.72
481.06
-77.61% 33.36%
244.6M
4.2M
-16.55% 51.92%
-1.96
58.8
-66.30% 48.24%
22.1M
2.1M
40.11% 239.32%
-0.95
7.61
-13.45% 69.54%

CorMedix Inc News

Latest updates
The Globe and Mail06 Jun 202410:53 am
InvestorPlace11 months ago

CorMedix Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue---29,7026,81721,2537,63622,86238,0888,19188,26155,71493,02016,44374,05424,77859,53035,266163,69226,523372,5147,550
Cost Of Revenue-818,539-4061,4693321,52748,00725,16614,42661,33957,23279,91319,18448,51746,12579,02621,128226,95522,114312,43433,663
Gross Profit-Infinity%-818,539-29,2965,34820,9216,1098,39012,922-6,23526,922-1,51813,107-2,74125,537-21,347-19,49614,138-63,2634,40960,080-26,112
Operating Expenses44.2%15,885,69711,017,1798,418,5246,967,2828,261,3667,038,4707,788,3108,577,8415,875,9937,237,4406,083,1226,616,8628,917,8685,637,2855,354,4775,152,0195,551,4944,859,918-2,133,82210,301,5338,546,038
  S&GA Expenses97.8%15,048,2527,609,6775,575,3024,628,0145,051,8954,750,8834,553,0913,836,6133,355,7904,601,1083,788,6933,691,5073,232,5763,165,1682,677,4702,631,0272,571,5871,984,9222,213,4402,012,4391,945,825
  R&D Expenses-75.4%837,4453,407,5022,843,2232,339,2683,209,4712,287,5873,235,2194,741,2282,520,2032,636,3322,294,4292,925,3555,685,2922,472,1172,677,0082,520,9922,979,9072,874,996-4,347,2618,289,0946,600,213
EBITDA Margin-22.8%-632-515-472-594-760-1,040-1,961-141-111-105-111----------
Interest Expenses12.1%9,8358,7768,7768,7763,5855,3785,3785,381-5,1845,3227,80013,8286,2766,276172,429306,736302,048---
Income Taxes-Infinity%-1,394,770----585,617----1,250,186---3,138-5,169,3956,276---5,060,778----
Earnings Before Taxes-50.1%-15,860,893-10,567,226-8,208,951-6,853,721-8,190,456--7,790,987-8,569,366-5,883,121--6,086,945-6,600,747-8,951,819--5,304,185-5,264,847-5,756,936-5,412,604-10,236,119-8,556,911
EBT Margin-22.7%-634-517-474-596-762-1,043-1,966-142-112-106-112----------
Net Income-36.9%-14,466,123-10,567,226-8,208,951-6,853,721-7,604,839-7,034,194-7,790,987-8,569,366-4,632,935-7,216,938-6,086,945-6,600,747-3,782,424-5,557,567-5,304,185-5,264,847-696,158-5,167,8842,148,518-10,236,119-8,556,911
Net Income Margin-51.2%-768-508-454-556-776-1,032-1,958-139-100-93.46-92.08----------
Free Cashflow-66.9%-17,371,600-10,408,652-6,283,594-6,071,854-5,471,978-6,748,666-6,498,121-6,281,407-3,097,132-6,703,892-6,010,571----------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-17.1%68.0082.0091.0057.0059.0062.0062.0068.0065.0069.0075.0081.0084.0049.0040.0024.0027.0029.0034.0028.0027.00
  Current Assets-20.2%63.0079.0089.0055.0057.0060.0060.0065.0063.0066.0073.0080.0083.0048.0039.0024.0027.0029.0034.0027.0027.00
    Cash Equivalents-19.4%35.0044.0053.0020.0025.0043.0043.0049.0046.0054.0067.0073.0076.0042.0035.0017.0012.0017.0020.0015.0018.00
  Inventory10.2%2.002.00----269*0.000.000.000.000.000.000.000.000.000.000.000.000.000.00
  Net PPE2.1%2.002.002.002.002.002.002.001.001.001.001.000.000.000.000.000.000.000.000.000.000.00
Liabilities-16.0%10.0012.008.008.005.007.006.006.005.006.006.004.004.005.006.006.006.006.005.0011.0011.00
  Current Liabilities-16.4%10.0011.008.007.005.006.005.005.004.005.005.003.003.004.005.006.006.006.005.004.004.00
Shareholder's Equity-17.3%58.0070.0083.0049.0054.0055.0056.0062.0060.0063.0069.0077.0080.0044.0034.000.0022.0024.0029.0016.0017.00
  Retained Earnings-4.5%-336-321-306-297-285-275-267-260-252-245-237-229-224-217-211-204-200-195-190-184-184
  Additional Paid-In Capital0.6%394392390346340330323322312308307306305262246223222219219201201
Shares Outstanding0.0%55.0055.0055.0046.0044.0043.0041.0039.0038.0038.0038.0038.0036.0034.00-------
Float----180---164---208---208---209-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-61.1%-17,310-10,745-8,697-8,572-10,393-6,154-5,995-5,462-6,744-5,869-5,503-3,091-6,690-5,933-7,312-754-7,966-3,884-3,964164-7,367
  Share Based Compensation100.8%2,4441,2171,0031,0572,2168749841,0741,1381,2531,0481,0101,732516611696677453571606809
Cashflow From Investing1396.3%8,945598-586-2,385-14,686-1.86-114594-4,187-7,129-1,271-208-526-1,8473,2435,045985296-477-3,874-7,964
Cashflow From Financing-120.8%-97.1246842,8995,3507,2006,0464378,4113,004--17741,58115,32221,943-2,835-20510,02914.0015,968
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

CRMD Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Revenues, net
Cost of sales(818,539)
Gross loss(818,539)
Operating Expenses  
Research and development(837,445)(3,407,502)
Selling, general and administrative(15,048,252)(7,609,677)
Total operating expenses(15,885,697)(11,017,179)
Loss From Operations(16,704,236)(11,017,179)
Other Income (Expense)  
Interest income857,186446,384
Foreign exchange transaction (loss) gain(4,008)12,345
Interest expense(9,835)(8,776)
Total other income843,343449,953
Net Loss Before Income Taxes(15,860,893)(10,567,226)
Tax benefit1,394,770
Net Loss(14,466,123)(10,567,226)
Other Comprehensive (Loss) Income  
Unrealized (loss) gain from investment(10,903)16,393
Foreign currency translation gain2562,096
Total other comprehensive (loss) income(10,647)18,489
Other Comprehensive Loss$ (14,476,770)$ (10,548,737)
Net Loss Per Common Share - Basic (in Dollars per share)$ (0.25)$ (0.24)
Weighted Average Common Shares Outstanding - Basic (in Shares)57,503,15444,090,998

CRMD Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Current assets  
Cash and cash equivalents$ 35,180,529$ 43,642,684
Restricted cash75,54077,453
Short-term investments23,370,98932,388,130
Inventories2,320,3962,106,345
Prepaid research and development expenses295,845353,574
Other prepaid expenses and current assets2,166,267882,214
Total current assets63,409,56679,450,400
Property and equipment, net1,905,7041,866,224
License intangible asset2,000,000
Restricted cash, long-term103,838103,055
Operating lease right-of-use asset604,634640,278
TOTAL ASSETS68,023,74282,059,957
Current liabilities  
Accounts payable2,826,3224,279,679
Accrued expenses6,553,3116,970,217
Operating lease liability, short-term154,801150,619
Total current liabilities9,534,43411,400,515
Operating lease liability, net of current portion476,588517,013
TOTAL LIABILITIES10,011,02211,917,528
COMMITMENTS AND CONTINGENCIES (Note 4)
STOCKHOLDERS’ EQUITY  
Preferred stock - $0.001 par value: 2,000,000 shares authorized; 181,622 shares issued and outstanding at March 31, 2024 and December 31, 2023182182
Common stock - $0.001 par value: 160,000,000 shares authorized; 54,959,270 and 54,938,258 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively54,95954,938
Accumulated other comprehensive gain83,46194,108
Additional paid-in capital394,040,254391,693,214
Accumulated deficit(336,166,136)(321,700,013)
TOTAL STOCKHOLDERS’ EQUITY58,012,72070,142,429
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$ 68,023,742$ 82,059,957
CRMD
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath and Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
 CEO
 WEBSITEcormedix.com
 INDUSTRYBiotechnology
 EMPLOYEES40

CorMedix Inc Frequently Asked Questions


What is the ticker symbol for CorMedix Inc? What does CRMD stand for in stocks?

CRMD is the stock ticker symbol of CorMedix Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of CorMedix Inc (CRMD)?

As of Wed Jun 12 2024, market cap of CorMedix Inc is 274.25 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CRMD stock?

You can check CRMD's fair value in chart for subscribers.

What is the fair value of CRMD stock?

You can check CRMD's fair value in chart for subscribers. The fair value of CorMedix Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of CorMedix Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CRMD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is CorMedix Inc a good stock to buy?

The fair value guage provides a quick view whether CRMD is over valued or under valued. Whether CorMedix Inc is cheap or expensive depends on the assumptions which impact CorMedix Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CRMD.

What is CorMedix Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Jun 12 2024, CRMD's PE ratio (Price to Earnings) is -5.46 and Price to Sales (PS) ratio is 4.55 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CRMD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on CorMedix Inc's stock?

In the past 10 years, CorMedix Inc has provided -0.043 (multiply by 100 for percentage) rate of return.